Transformative therapeutic approach based on a unique protein: IGFBPL1
To halt disease progression, therapeutics must mitigate toxic neuroinflammation and promote retinal ganglion cell survival. These two processes cannot be effectively modulated by a single target.
IGFBPL1: The first multi-targeting, multifunctional therapeutic protein for glaucoma and other ophthalmologic diseases.
FireCyte discovered that a natural protein produced in the human CNS interacts with two distinct targets, creating a novel combination of pharmacology uniquely beneficial for neurodegenerative diseases. Loss of IGFBPL1 leads to development of normotensive glaucoma and tauopathies.1
Sortilin 1 (SORT1)
- Identified due to its link with Alzheimer’s disease.
- Modulates processes integral to inflammation and stress response.
- Expressed by both microglia and neurons.
- IGFBPL1 inhibits SORT1.
- A growth-factor like receptor in neurons.
- Promotes neuronal survival, regulates axon guidance and promotes neurite outgrowth (especially during development).
- Expressed by neurons.
- IGFBPL1 modulates DCC.
SOURCE Images courtesy of the National Center for Biotechnology Information
1 www.firecyte.com/wp-content/uploads/2024/06/2023-Cell-Rep-IGBPL1-Master-Driver-Microglia.pdf